高级检索
当前位置: 首页 > 详情页

Flavonoids as human carboxylesterase 2 inhibitors: Inhibition potentials and molecular docking simulations

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Hepat Surg Ctr, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China [2]Dalian Med Univ, Natl & Local Joint Engn Res Ctr Drug Dev Neurodeg, Coll Pharm, Coll Inst Integrat Med, Dalian 116044, Liaoning, Peoples R China
出处:
ISSN:

关键词: Human carboxylesterase 2 Flavonoids Molecular docking

摘要:
In our search for natural human carboxylesterase 2 (hCE 2) inhibitors from natural products, we investigated inhibitory effects and mechanisms of flavonoids (1-16) against hCE 2. The results demonstrated that kurarinone (1), baicalein (2), 2-[(2'-(1-hydroxy-1-methylethyl)-7'-(3-methyl-2-butenyl)-2',3'-dihydrobenzofuran)-5-yl]-7-hydroxy-8-(3-methyl-2-butenyl)chroman-4-one (5), luteolin (6), kushenol X (9), and kushenol C (11) displayed significantly inhibitory effects against hCE 2 with IC50 values of 1.46 +/- 0.43, 5.22 +/- 0.89, 1.13 +/- 0.19, 9.78 +/- 0.98, 3.05 +/- 0.46, and 2.61 +/- 0.52 mu M, respectively. Compounds 1, 5, 6, 9, and 11 were all uncompetitive inhibitors with Ki values of 1.73, 1.59, 16.89, 1.72, and 0.79 mu M, respectively, and their Km values ranged from 2.08 mu M to 5.41 mu M. Furthermore, molecular docking was conducted for investigating mechanisms of compounds 1, 5, 6, 9, and 11 with hCE 2. These results suggested that compounds 1, 5, 6, 9, and 11 could be served as lead compounds for the development of novel hCE 2 inhibitors. 2019 Published by Elsevier B.V.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 生物
小类 | 2 区 应用化学 2 区 高分子科学 3 区 生化与分子生物学
最新[2025]版:
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 应用化学 2 区 高分子科学
JCR分区:
出版当年[2017]版:
Q1 POLYMER SCIENCE Q1 CHEMISTRY, APPLIED Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2023]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 CHEMISTRY, APPLIED Q1 POLYMER SCIENCE

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Hepat Surg Ctr, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China
通讯作者:
通讯机构: [2]Dalian Med Univ, Natl & Local Joint Engn Res Ctr Drug Dev Neurodeg, Coll Pharm, Coll Inst Integrat Med, Dalian 116044, Liaoning, Peoples R China [*1]Dalian Med Univ, Coll Pharm, 9 West Sect Lushun South Rd, Dalian 116044, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:1 总访问量:411 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)